Compare ONC & STLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | STLD |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 33.0B |
| IPO Year | 2015 | 1996 |
| Metric | ONC | STLD |
|---|---|---|
| Price | $374.47 | $228.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $385.10 | $210.00 |
| AVG Volume (30 Days) | 368.0K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 0.94% |
| EPS Growth | ★ 140.43 | N/A |
| EPS | 0.31 | ★ 6.47 |
| Revenue | $238,387,000.00 | ★ $22,260,774,000.00 |
| Revenue This Year | $723.76 | $17.86 |
| Revenue Next Year | $15.04 | $2.86 |
| P/E Ratio | $1,191.16 | ★ $33.85 |
| Revenue Growth | ★ 22179.16 | 20.92 |
| 52 Week Low | $253.95 | $126.88 |
| 52 Week High | $385.22 | $288.74 |
| Indicator | ONC | STLD |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 36.15 |
| Support Level | $325.47 | $217.70 |
| Resistance Level | $385.22 | $243.73 |
| Average True Range (ATR) | 8.06 | 9.48 |
| MACD | 2.02 | -4.90 |
| Stochastic Oscillator | 94.29 | 15.53 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Steel Dynamics Inc operates as a domestic steel producer and metal recycler in the United States. The company's product portfolio comprises hot rolled sheet, hot rolled plate, painted sheet products, cold rolled sheet, and others. Its reportable segments are steel operations, metals recycling operations, steel fabrication operations, and aluminum operations. Maximum revenue is generated from its steel operations segment, which consists of manufacturing various steel products and numerous coating operations. Its primary sources of revenue are currently from the manufacture and sale of steel products, the processing and sale of recycled ferrous and nonferrous metals, and the fabrication and sale of steel joists and deck products.